Literature DB >> 12019082

Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus.

B Hernandez-Santiago1, L Placidi, E Cretton-Scott, A Faraj, E G Bridges, M L Bryant, J Rodriguez-Orengo, J L Imbach, G Gosselin, C Pierra, D Dukhan, J P Sommadossi.   

Abstract

beta-L-Thymidine (L-dT) and beta-L-2'-deoxycytidine (L-dC) are potent and highly specific inhibitors of hepatitis B virus (HBV) replication both in vivo and in vitro (50% effective concentrations, 0.19 to 0.24 microM in 2.2.15 cells). The intracellular metabolisms of L-dT and L-dC were investigated in HepG2 cells and primary cultured human hepatocytes. L-dT and L-dC were extensively phosphorylated in both cell types, with the 5'-triphosphate derivative being the predominant metabolite. In HepG2 cells, the 5'-triphosphate levels were 27.7 +/- 12.1 and 72.4 +/- 1.8 pmol/10(6) cells for L-dT and L-dC, respectively. In primary human hepatocytes, the 5'-triphosphate levels were 16.5 +/- 9.8 and 90.1 +/- 36.4 pmol/10(6) cells for L-dT and L-dC, respectively. Furthermore, a choline derivative of L-dCDP was detected at concentrations of 15.8 +/- 1.8 and 25.6 +/- 0.1 pmol/10(6) cells in human hepatocytes and HepG2 cells, respectively. In HepG2 cells exposed to L-dC, the 5'-monophosphate and 5'-triphosphate derivatives of beta-L-2'-deoxyuridine (L-dUMP and L-dUTP, respectively) were also observed, reaching intracellular concentrations of 6.7 +/- 0.4 and 18.2 +/- 1.0 pmol/10(6) cells, respectively. In human hepatocytes, L-dUMP and L-dUTP were detected at concentrations of 5.7 +/- 2.4 and 43.5 +/- 26.8 pmol/10(6) cells, respectively. It is likely that deamination of L-dCMP by deoxycytidylate deaminase leads to the formation of L-dUMP, as the parent compound, L-dC, was not a substrate for deoxycytidine deaminase. The intracellular half-lives of L-dTTP, L-dCTP, and L-dUTP were at least 15 h, with intracellular concentrations of each metabolite remaining above their respective 50% inhibitory concentrations for the woodchuck hepatitis virus DNA polymerase for as long as 24 h after removal of the drug from cell cultures. Exposure of HepG2 cells to L-dT in combination with L-dC led to concentrations of the activated metabolites similar to those achieved with either agent alone. These results suggest that the potent anti-HBV activities of L-dT and L-dC are associated with their extensive phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019082      PMCID: PMC127241          DOI: 10.1128/AAC.46.6.1728-1733.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication.

Authors:  C N Chang; S L Doong; J H Zhou; J W Beach; L S Jeong; C K Chu; C H Tsai; Y C Cheng; D Liotta; R Schinazi
Journal:  J Biol Chem       Date:  1992-07-15       Impact factor: 5.157

Review 2.  Hepatitis B virus. The major etiology of hepatocellular carcinoma.

Authors:  R P Beasley
Journal:  Cancer       Date:  1988-05-15       Impact factor: 6.860

3.  Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase.

Authors:  D S Shewach; D C Liotta; R F Schinazi
Journal:  Biochem Pharmacol       Date:  1993-04-06       Impact factor: 5.858

4.  Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine.

Authors:  R Ling; D Mutimer; M Ahmed; E H Boxall; E Elias; G M Dusheiko; T J Harrison
Journal:  Hepatology       Date:  1996-09       Impact factor: 17.425

Review 5.  Hepatitis B: global importance and need for control.

Authors:  J E Maynard
Journal:  Vaccine       Date:  1990-03       Impact factor: 3.641

6.  Antiviral L-nucleosides specific for hepatitis B virus infection.

Authors:  M L Bryant; E G Bridges; L Placidi; A Faraj; A G Loi; C Pierra; D Dukhan; G Gosselin; J L Imbach; B Hernandez; A Juodawlkis; B Tennant; B Korba; P Cote; P Marion; E Cretton-Scott; R F Schinazi; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

Authors:  P A Furman; M Davis; D C Liotta; M Paff; L W Frick; D J Nelson; R E Dornsife; J A Wurster; L J Wilson; J A Fyfe
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

8.  Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells.

Authors:  M T Paff; D R Averett; K L Prus; W H Miller; D J Nelson
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  Comparative metabolism of 3'-azido-3'-deoxythymidine in cultured hepatocytes from rats, dogs, monkeys, and humans.

Authors:  F Nicolas; G De Sousa; P Thomas; M Placidi; G Lorenzon; R Rahmani
Journal:  Drug Metab Dispos       Date:  1995-03       Impact factor: 3.922

View more
  14 in total

1.  Presteady state kinetic investigation of the incorporation of anti-hepatitis B nucleotide analogues catalyzed by noncanonical human DNA polymerases.

Authors:  Jessica A Brown; Lindsey R Pack; Jason D Fowler; Zucai Suo
Journal:  Chem Res Toxicol       Date:  2011-12-16       Impact factor: 3.739

2.  Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment.

Authors:  Xiao-Jian Zhou; Thomas C Marbury; Harry W Alcorn; William B Smith; Gloria Dubuc Patrick; George C Chao; Nathaniel A Brown
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

Review 3.  Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy.

Authors:  Erik De Clercq; Hugh J Field
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues.

Authors:  E Matthes; A Funk; I Krahn; K Gaertner; M von Janta-Lipinski; L Lin; H Will; H Sirma
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

5.  Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.

Authors:  Xiao-Jian Zhou; Suzanne Swan; William B Smith; Thomas C Marbury; Gloria Dubuc-Patrick; George C Chao; Nathaniel A Brown
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

6.  Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications.

Authors:  Xiao-Jian Zhou; Seng-Gee Lim; Deborah M Lloyd; George C Chao; Nathaniel A Brown; Ching-Lung Lai
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

7.  Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B.

Authors:  Edward G Bridges; Jules R Selden; Shouqi Luo
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

8.  Cellular pharmacology of the anti-hepatitis B virus agent beta-L-2',3'-didehydro-2',3'-dideoxy-N4-hydroxycytidine: relevance for activation in HepG2 cells.

Authors:  E Matthes; H Bünger
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

9.  Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2',3'-didehydro-2',3'-dideoxythymidine in cells.

Authors:  Rong Hu; Ling Li; Bart Degrève; Ginger E Dutschman; Wing Lam; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.938

10.  Antiviral treatment of chronic hepatitis B virus (HBV) infections.

Authors:  Erik De Clercq; Geoffrey Férir; Suzanne Kaptein; Johan Neyts
Journal:  Viruses       Date:  2010-05-31       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.